Talat Imran - 29 Jul 2021 Form 3/A - Amendment Insider Report for Rani Therapeutics Holdings, Inc. (RANI)

Role
Chief Executive Officer, Director
Signature
/s/ Josh Seidenfeld, Attorney-in-Fact for Talat Imran
Issuer symbol
RANI
Transactions as of
29 Jul 2021
Net transactions value
$0
Form type
3/A - Amendment
Filing time
02 Aug 2021, 19:27:35 UTC
Date Of Original Report
29 Jul 2021
Next filing
13 Sep 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding RANI Class A Common Stock 829,435 29 Jul 2021 See footnote F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding RANI Class A Common LLC Units 29 Jul 2021 Class A Common Stock 43,421 Direct F1, F3
holding RANI Stock Option (Right to Buy) 29 Jul 2021 Class A Common Stock 78,877 $9.45 Direct F1, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This amendment is being filed to correctly reflect the shares held directly and indirectly.
F2 Represents 378,533 shares of Class A Common Stock of the Issuer ("Class A Shares") held by Biologix Partners, LP and 450,902 Class A Shares held by VH Rani, LP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
F3 Represents Class A Common LLC Units of Rani Therapeutics, LLC, a direct subsidiary of the Issuer. The Class A Common LLC Units are exchangeable for shares of Class A Common Stock on a one-for-one basis at the discretion of the holder, subject to certain exceptions, conditions and adjustments, and have no expiration date.
F4 The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from June 17, 2021.
F5 This amendment is being filed to correctly reflect the exercise price of the Stock Option.